A semi-automated method for measuring the potential for protein covalent binding in drug discovery

Banks, 1995, Diclofenac-associated hepatotoxicity: Analysis of 180 cases reported to the food and drug administration as adverse reactions, Hepatology, 22, 820, 10.1002/hep.1840220320 Chauret, 1995, Microsomal metabolism of the 5-lipoxygenase inhibitors L-746530 and L-739010 to reactive intermediates that covalently bind to protein: The role of the 6,8-dioxobicyclo[3.2.1]octanyl moiety, Drug Metabolism and Disposition, 23, 1325 Day, 1999, Semi-automated assay for covalent protein binding of drug candidates, ISSX Proceedings, 15, 86 Evans, 2004, Drug–protein adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development, Chemical Research in Toxicology, 17, 3, 10.1021/tx034170b Koyama, 1997, Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: A study using microsomes from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs, Journal of Pharmacology and Experimental Therapeutics, 281, 1199 Lu, 1972, Partial purification of cytochromes P-450 and P-448 from rat liver microsomes, Biochemica and Biophysical Research Communication, 46, 1334, 10.1016/S0006-291X(72)80121-9 Masubuchi, 1996, Imipramine-induced inactivation of a cytochrome P450 2D enzyme in rat liver microsomes in relation to covalent binding of its reactive intermediates, Journal of Pharmacology and Experimental Therapeutics, 279, 724 Ouellette, 1991, Reversible hepatitis associated with diclofenac, Journal of Clinical Gastroenterology, 13, 205, 10.1097/00004836-199104000-00018 Park, 1998, Role of drug disposition in drug hypersensitivity: A chemical, molecular, and clinical perspective, Chemical Research in Toxicology, 11, 969, 10.1021/tx980058f Pohl, 1981, Covalent binding of electrophilic metabolites to macromolecules, Methods in Enzymology, 77, 43, 10.1016/S0076-6879(81)77009-5 Schwarz, 1980, Effect of decreased glucuronidation and sulfation on covalent binding of naphthalene in isolated rat hepatocytes, Toxicology, 17, 119, 10.1016/0300-483X(80)90083-9 Shen, 1999, Metabolic activation of diclofenac by human cytochrome P450 3A4: Role of 5-hydroxydiclofenac, Chemical Research in Toxicology, 12, 214, 10.1021/tx9802365 Short, 1968, Cholestatic jaundice during imipramine therapy, Journal of the Americal Medical Association, 206, 1791, 10.1001/jama.1968.03150080071021 Tang, 1999, Studies on cytochrome P-450-mediated bioactivation of diclofenac in rats and in human hepatocytes: Identification of glutathione conjugated metabolites, Drug Metabolism and Disposition, 27, 365 Tsuruda, 1995, Formation of epoxide and quinone protein adducts in B6C3F1 mice treated with naphthalene, sulfate conjugate of 1,4-dihydroxynaphthalene and 1,4-naphthoquinone, Archieve in Toxicology, 69, 362, 10.1007/s002040050185 Uetrecht, 2000, Is it possible to more accurately predict which drug candidates will cause idiosyncratic drug reactions?, Current Drug Metabolism, 1, 133, 10.2174/1389200003339081 Zhang, 1996, Microsomal metabolism of the 5-lipoxygenase inhibitor L-739,010: Evidence for furan bioactivation, Chemical Research in Toxicology, 9, 547, 10.1021/tx950183g